A rare case of late-onset lichenoid photodermatitis after vandetanib therapy.

摘要: Vandetanib (ZD6474, Zactima) is a novel inhibitor of multiple tyrosine kinases that has been used for the treatment various malignancies including medullary thyroid carcinoma.1 The drug functions primarily via inhibitory effects on vascular endothelial growth factor receptors, epidermal and RET-tyrosine kinase system.2 As with other targeted chemotherapy agents, several cutaneous side folliculitis, palmar-plantar hyperkeratosis, desquamation, hyperpigmentation, photosensitization have reported.3, 4 Photosensitivity, although less commonly reported, was found to make up 37% adverse in one case series.3 Most these patients were exhibit sunburnlike erythema sun-exposed regions subsequent desquamation. However, small subset exhibited phenotypically lichenoid photodermatitis lymphocytic interface dermatitis basal vacuolization keratinocyte apoptosis upon histopathology. Only handful cases describing similar eruptions after vandetanib use most which developed within few weeks exposure.5, 6, 7, 8 We present patient late-onset began 5 months initiation therapy.